# Association between estrogen receptor gene polymorphisms and premature thelarche

Jong Seo Yoon<sup>1</sup>, Hae Sang Lee<sup>1</sup>, Jung Sub Lim<sup>2</sup>, Jin Soon Hwang<sup>1</sup>

<sup>1</sup>Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, Republic of Korea <sup>2</sup>Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Republic of Korea

### Introduction

Premature thelarche (PT) is a benign, non-progressive condition defined as isolated breast development without the activation of the hypothalamic-pituitary axis.<sup>1</sup> While the pathophysiology of PT remains unclear, increased sensitivity to estrogen may cause PT.<sup>2</sup>

Table 3. Frequencies of polymorphisms for estrogen receptor  $\alpha$  (ER $\alpha$ ) Pvull and Xbal genotypes between girls with premature thelarche (PT) and controls

	PT girls (n=96)	Controls (n=100)	P value
Pvull polymorphism			
CC	12 (12.5%)	22 (22.0%)	0.079
TC	51 (53.1%)	41 (41.0%)	0.089
TT	33 (34.3%)	37 (37.0%)	0.520
Xbal polymorphism			
GG	2 (2.0%)	4 (4.0%)	0.436
AG	31 (32.3%)	25 (25.0%)	0.259
AA	63 (65.6%)	71 (71.0%)	0.419

## Objectives

The aim of this study was to investigate the association between polymorphisms in the estrogen receptor alpha ( $ER\alpha$ ) gene and PT in girls.

# Methods

In this case-control study, we examined 96 girls referred for early breast development (before the age of 8 years). The control group included healthy Korean females with normal pubertal progression. Anthropometric and hormonal parameters were measured and *Pvull and Xbal ERa* gene polymorphisms were evaluated by PCR. Out of the 96 girls, all coding exon and exon-intron boundaries of *ERa* were sequenced from the DNA of 46 girls.

#### Results

Table 4. Association of X*ba*l polymorphism of estrogen receptor  $\alpha$  (ERa) with Tanner stage in girls with premature thelarche

Characteristics	AA (n=63)	GG and AG (n=33)	P value*	Odds ratio (95% CI)
Tanner stage (Breast)			0.018	3.073 (1.183-7.979)
Tanner stage 2	52 (82.5%)	20 (60.6%)		
Tanner stage 3	11 (17.5%)	13 (39.4%)		

\* The proportion of Tanner stage was compared using the chi square test depending on Xbal polymorphism

There was no significant difference in the distribution of *Pvull* and *Xbal* polymorphisms between patients and controls. However, the carriers of *Xbal* polymorphisms had more advanced Tanner stage than did the non-carriers. Also, four *ERa* gene polymorphisms were previously identified, but these polymorphisms had no clinical significance.

Table 1. Clinical and laboratory characteristics of the subjects

Characteristics	<b>Total (n=96)</b>
Age at examination (year)	8.21 ± 0.61
Height SDS	$1.09 \pm 0.88$
Weight SDS	$1.10 \pm 0.90$
BMI SDS	$0.85 \pm 1.00$
Bone age (years)	$10.4 \pm 0.8$
Basal LH (IU/L)	$1.1 \pm 0.5$
Basal FSH (IU/L)	1.9 ± 1.6
Basal E2 (pg/mL)	8.0 ± 4.1
Peak LH (IU/L)	$3.3\pm0.9$
Peak FSH (IU/L)	11.8 ± 6.5
Peak E2 (pg/mL)	9.1 ± 4.7
Feak EZ (pg/IIIL)	9.1 ± 4.7

Table 2. Allele frequencies of the ERa polymorphisms form 96 patients and 102 controls.



No association was found between the  $ER\alpha$  gene polymorphisms and PT in girls. However, *Xbal* polymorphisms may contribute to early breast budding. Further studies are needed to validate the role of  $ER\alpha$  gene polymorphisms in PT.

## References

1. Pescovitz OH, Hench KD, Barnes KM et al. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1988; 67: 474-479

2. Rosenfield RL. Normal and almost normal precocious variations in pubertal development premature pubarche and premature thelarche revisited. Horm Res 1994; 41 Suppl 2: 7-13

No				Allele frequency					
No.	Location	dbSNP ID	Polymorphism	Group	1		2		*P-value
1	Exon1	rs2077647	152129077 T/C	Patient	62	0.673	30	0.327	0.243
			T=1; C=2	Control	123	0.603	81	0.397	
2	Exon1	rs17847065	152129484 C/A	Patient	90	0.978	2	0.022	0.560
			C=1; A=2	Control	197	0.966	7	0.034	
3	Exon4	rs1801132	152265522 C/G	Patient	51	0.554	41	0.446	0.995
			C=1; G=2	Control	113	0.554	91	0.446	
4	Exon8	rs2228480	152420095 G/A	Patient	80	0.869	12	0.131	0.170
			G=1; A=2	Control	164	0.804	40	0.196	

\*Comparison of the allele frequencies between the patient group and the control group The positions of the polymorphisms were defined according to contig NT\_025741.15

In relation to this presentation, I declare that there are no conflicts of interest.

